Showing 461 - 480 results of 99,982 for search '(( 12 men decrease ) OR ( 5 ((((point decrease) OR (fold decrease))) OR (a decrease)) ))', query time: 1.23s Refine Results
  1. 461
  2. 462
  3. 463
  4. 464
  5. 465
  6. 466
  7. 467
  8. 468
  9. 469

    Dox-inducible expression of HA-MAD1 in colon is sufficient to decrease p53 expression and cause chromosome missegregation. by Sarah E. Copeland (13951506)

    Published 2024
    “…Large circles show mean of cells from 5 fields of view from a single animal. (D) Immunoblot showing p53 protein expression is decreased in colon tissue from 5-month old HA-MAD1 mice after 1 week of 6 mg/kg dox feed as compared to control. …”
  10. 470

    VRK1 overexpression is seen in human breast cancer and is associated with decreased relapse-free survival. by Aye M. Mon (5714912)

    Published 2018
    “…Data for cancer subtypes are shown in boxes numbered 1–11: 1: benign breast neoplasm (rank 6459, 1.4 fold-change, NS), 2: breast carcinoma (rank 833, 1.5 fold-change, p = 3.83x10<sup>-5</sup>), 3: breast phyllodes tumor (rank 512, 1.2 fold-change, p = 0.002), 4: ductal breast carcinoma in situ (rank 1969, 1.5 fold-change, p = 0.002), 5: invasive breast carcinoma (rank 1060, 1.6 fold-change, p = 1.28x10<sup>-5</sup>), 6: invasive ductal and invasive lobular breast carcinoma (rank 941, 1.5 fold-change, p = 6.76x10<sup>-22</sup>), 7: invasive ductal breast carcinoma (rank 613, 1.5-fold change, p = 2.71x10<sup>-71</sup>), 8: invasive lobular breast carcinoma (rank 947, 1.3 fold-change, p = 3.64x10<sup>-28</sup>), 9: medullary breast carcinoma (rank 400, 1.8 fold-change, p = 3.25x10<sup>-12</sup>), 10: mucinous breast carcinoma (rank 1932, 1.4 fold-change, p = 7.41x10<sup>-10</sup>) and 11: tubular breast carcinoma (rank 1253, 1.4 fold-change, p = 1.24x10<sup>-17</sup>). …”
  11. 471
  12. 472

    Possible Points of Canonical Wnt Inhibition. by Laura Corbett (826084)

    Published 2015
    “…<p>This study has highlighted six possible points of canonical Wnt inhibition occurring in HSCs. (1) Predominantly non-canonical ligand expression. …”
  13. 473
  14. 474

    OCA alone markedly decreases and combined with Gemcitabine or Cisplatin abrogates growth of iCCA xenografts. by S. Di Matteo (6260417)

    Published 2019
    “…After 4 weeks, when the tumor size was approximately 100 mm<sup>3</sup> (T<sub>0</sub>) mice were treated with OCA (0.03% w/w, 30 mg/kg) alone or combined with Cisplatin (2.4 mg/Kg in 100 μl) or Gemcitabine (1.05 mg/Kg in 100 μl) for 5 additional weeks. a) Results are expressed as percent increase in tumor volume at different time points. …”
  15. 475
  16. 476
  17. 477
  18. 478
  19. 479
  20. 480